Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

  1. Mona Ariamanesh
  2. Pejman Porouhan
  3. Babak PeyroShabany
  4. Danial Fazilat-Panah
  5. Mansoureh Dehghani
  6. Maryam Nabavifard
  7. Farbod Hatami
  8. Mohammad Fereidouni
  9. James S. Welsh
  10. Seyed Alireza Javadinia

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1080/07357907.2021.1992420
  2. ScreenIT

    SciScore for 10.1101/2021.09.02.21262760: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The protocol of the study was approved by the Ethics Committee of Sabzevar University of Medical Sciences (IR.MEDSAB.REC.1400.027) and a written informed consent form was obtained from the patients or the legal guardian. 2.2. Measurements: At baseline, the previous history of confirmed COVID-19 with real-time polymerase chain reaction (PCR) was assessed and blood samples were drawn to measure anti-SARS-CoV-2 Nucleocapsid (N) IgG [PISHTAZTEB DIAGNOSTICS, Tehran, Iran].
    Consent: The protocol of the study was approved by the Ethics Committee of Sabzevar University of Medical Sciences (IR.MEDSAB.REC.1400.027) and a written informed consent form was obtained from the patients or the legal guardian. 2.2. Measurements: At baseline, the previous history of confirmed COVID-19 with real-time polymerase chain reaction (PCR) was assessed and blood samples were drawn to measure anti-SARS-CoV-2 Nucleocapsid (N) IgG [PISHTAZTEB DIAGNOSTICS, Tehran, Iran].
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Two months following vaccination, blood samples were drawn to analyze the presence of SARS-CoV-2 anti-Spike protein (S) IgG and neutralizing antibodies.
    neutralizing antibodies
    suggested: None
    According to the kits’ manual, a cut-off points of 8 μg/ml and 2.5 μg/ml were considered as positive response for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2-neutralizing antibody respectively.
    Anti-Spike IgG
    suggested: None
    SARS-CoV2-neutralizing
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are some limitations. For example, although this study assessed the short-term serologic and clinical efficacy of BBIBP-CorV vaccine, longer follow up is essential to confirm the long-term effects, need for further boost dose, and efficacy against newer variants of SARS-CoV-2.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.09.02.21262760v2 on medRxiv
  4. Version published to 10.1101/2021.09.02.21262760v1 on medRxiv